Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 75,176	$ 22,521
Restricted cash		13,098
Accounts receivables, net	14,768	14,454
Inventory	2,144	3,362
Prepaid expenses and other	13,900	14,153
Total current assets	105,988	67,588
Property and equipment, net	29,454	29,888
Operating lease right-of-use assets	44,833	46,384
Intangibles, net	79,967	63,308
Goodwill	38,298	38,298
Equity investments	256,420	262,241
Restricted cash	45,000	45,150
Other, net	2,125	4,775
Total assets	602,085	557,632
Current liabilities:
Accounts payable	22,849	27,630
Accrued payroll and related benefits	17,930	15,914
Accrued expenses	24,562	18,728
Current portion of deferred revenue	4,170	3,643
Acquisition consideration payable	398	908
Current portion of derivative liabilities		8,800
Current portion of debt	18,529	36,261
Current portion of operating lease liabilities	3,687	3,322
Total current liabilities	92,125	115,206
Long-term debt, net of discount	149,459	199,088
Deferred tax liabilities, net	7,055	9,043
Deferred revenue	113,477	114,389
Derivative liabilities	42,900	35,000
Operating lease liabilities	51,236	52,111
Other long-term liabilities	549	39
Total liabilities	456,801	524,876
Commitments and contingencies (See Note 10)
Sorrento Therapeutics, Inc. equity
Preferred stock, $0.0001 par value; 100,000,000 shares authorized and no shares issued or outstanding
Common stock, $0.0001 par value 750,000,000 shares authorized and 261,737,622 and 167,798,120 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	28	18
Additional paid-in capital	1,141,208	788,122
Accumulated other comprehensive gain (loss)	444	(270)
Accumulated deficit	(886,776)	(659,818)
Treasury stock, 7,568,182 shares at cost at September 30, 2020, and December 31, 2019	(49,464)	(49,464)
Total Sorrento Therapeutics, Inc. stockholders’ equity	205,440	78,588
Noncontrolling interests	(60,156)	(45,832)
Total equity	145,284	32,756
Total liabilities and stockholders’ equity	$ 602,085	$ 557,632